Tocilizumab for Patients with Severe Fever with Thrombocytopenia Syndrome: Tocilizumab Observational SFTS Study-1.

Yonsei Med J · 2025 · PMC12041401 · PMID 40288904

Europe PMC DOI

hedged sentences

0.0850

closest p · 1.7× alpha

0.6080

boldest claim

The sentences

a decreasing trendp =0.085so close (0.05 < p ≤ 0.1)

A decreasing trend in IL-6 levels was observed from the 6–10 day interval to the 21–30 day interval in the TPE group ( p =0.085).

also in 47,180 other papers

showed a trendp =0.608not close (p > 0.1)

Compared with TPE, TCZ treatment showed a trend towards lower mortality rate (14-day mortality rate: 10.0% vs. 16.7%, p =0.608; 28-day mortality rate: 10.0% vs. 20.0%, p =0.480).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.